Citations

Clear

2960 citation(s) found for "Kim, P".

Associations of High Attenuation Area–Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
Debban, Catherine L., Guzman, Daniel E., Hannan, Riley T. , Salvatore, Mary , Zhang, David , Podolanczuk, Anna J. , Ma, Shwu‐Fan , Huang, Yong , Rotter, Jerome I., Dubin, Ruth F. , Wang, Jennifer M. , Han, MeiLan K., Noth, Imre , Woodruff, Prescott G. , Ortega, Victor E. , Fanburg–Smith, Julie C. , Stelow, Edward B. , Moskaluk, Christopher A. , Hoffman, Eric A. , Barr, R. Graham , Hannan, Riley T , Zhang, David , Podolanczuk, Anna J , Ma, Shwu-Fan , Pugashetti, Janelle Vu , Wang, Jennifer M , Oldham, Justin M , Hoffman, Eric A , Garcia, Christine K , Kim, John S. , McGroder, Claire F. , Duprez, Daniel A. , Sturek, Jeffrey M , Rich, Stephen S. , Rotter, Jerome I. , Deo, Rajat , Han, MeiLan King , Bowler, Russell P. , Ganz, Peter , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 22, 2025 | Volume: 211 | Issue: 10 | Pages: 1811-1822

10.1164/rccm.202503-0610oc | PMID 40845333 Get It

Abstract Rationale High-attenuation area (HAA) is a computed tomography (CT) tool that correlates with lung inflammation and fibrosis. Systemic molecular correlates of HAA (e.g., plasma proteins) may inform biological processes involved in interstitial lung disease. Objectives To identify plasma proteins that associate with HAA and correlate with a higher probability of developing new-onset fibrotic or subpleural interstitial lung abnormalities (ILAs). Methods Plasma protein levels were measured using a semiquantitative aptamer-based platform in MESA (the Multi-Ethnic Study of Atherosclerosis; N = 5,486) and SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study; N = 1,781). Linear regression models identified HAA-associated proteins after adjustment for demographic and socioeconomic factors, CT scanner parameters, study center, and batch. Associations of HAA-related proteins with new-onset fibrotic or subpleural ILAs were examined in MESA participants with ILA assessments on full-lung CT 10 years later. Immunohistochemical staining of select proteins was performed in lung tissue from pulmonary fibrosis cases. Measurements and Main Results There were 75 proteins detected that were significantly associated with HAA in MESA and SPIROMICS. Gene Ontology analysis of these proteins identified processes involved in immune cell chemotaxis and cellular growth and apoptosis. Seven proteins were associated with a higher probability of new-onset fibrotic or subpleural ILAs in MESA, and two of these, junctional adhesion molecule-like protein and GTP cyclohydrolase 1 feedback regulatory protein, stained in areas of fibrosis in lung tissue from patients with interstitial lung disease. Conclusions Plasma proteins associated with more HAA are involved in immune and cellular processes and associate with new-onset fibrotic-subpleural ILA.
Understanding monocyte-driven neuroinflammation in Alzheimer’s disease using human cortical organoid microphysiological systems
Tian, Chunhui , Ao, Zheng , Cerneckis, Jonas , Cai, Hongwei , Niu, Hengyao , Takayama, Kazuo , Kim, Jungsu , Shi, Yanhong , Gu, Mingxia , Kanekiyo, Takahisa , Niu, Hengyao , Takayama, Kazuo , Kim, Jungsu , Gu, Mingxia , Kanekiyo, Takahisa , Guo, Feng , Tian, Chunhui , Chen, Lei

Mayo Clinic

Science Advances | August 22, 2025 | Volume: 11 | Issue: 34 | Pages: No page available

10.1126/sciadv.adu2708 | PMID 40845091 Get It

Increasing evidence strongly links neuroinflammation to Alzheimer’s disease (AD) pathogenesis. Peripheral monocytes are crucial components of the human immune system, but their contribution to AD pathogenesis is still largely understudied partially due to limited human models. Here, we introduce human cortical organoid microphysiological systems (hCO-MPSs) to study AD monocyte-mediated neuroinflammation. By culturing doughnut-shape organoids on 3D-printed devices within standard 96-well plates, we generate hCO-MPSs with reduced necrosis, minimized hypoxia, and improved viability. Using these models, we found that monocytes from AD patients exhibit increased infiltration ability, decreased amyloid-β clearance capacity, and stronger inflammatory response than monocytes from age-matched control donors. Moreover, we observed that AD monocytes induce pro-inflammatory effects such as elevated astrocyte activation and neuronal apoptosis. Furthermore, the marked increase in IL1B and CCL3 expression underscores their pivotal role in AD monocyte-mediated neuroinflammation. Our findings provide insight into understanding monocytes’ role in AD pathogenesis, and our lab-compatible MPS models may offer a promising way for studying various neuroinflammatory diseases.
Safety and efficacy of preoperative embolization in the treatment of brain arteriovenous malformations with perinidal aneurysms and single draining vein: a multicenter study with propensity score-weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Ogilvy, Christopher S. , Sheehan, Jason , Aslan, Assala , Patel, Pious D. , Lan, Matthews , Baldassari, Michael P. , Koduri, Sravanthi , Atallah, Elias , Zeineddine, Hussein A. , Pontarelli, Mary-Katharine , Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Başkaya, Mustafa K. , Ataoglu, Cagdas , Mccarthy, Finn, Sanchez‐Forteza, Anthony , Essibayi, Muhammed Amir , Muram, Sandeep , Sconzo, Daniel , Riina, Howard A. , Rezai, Arwin, Alwakaa, Omar , Erginoğlu, Ufuk , Sen, Rajeev , Devia, Diego A., Perez-Mendez, Wilfran, Puentes, Juan C. , Spiotta, Alejandro M , Puri, Ajit S , Singh, Jasmeet, Burkhardt, Jan Karl, Starke, Robert M., Sekhar, Laligam N., Haranhalli, Neil , McAvoy, Malia , Eltiti, Marah, Abushehab, Abdallah, Foreman, Paul M. , Zaidat, Osama O. , Ruppert-Gomez, Marcella , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M, Alshahrani, Rabab, Gooch, M Reid, Rosenwasser, Robert H. , Bulsara, Ketan R., Kan, Peter , Kim, Louis J. , Pukenas, Bryan , Li, Yan-Lin , Alaraj, Ali , Fuschi, Maurizio , Patel, Aman B. , Notarianni, Christina , Cuellar, Hugo H, Lawton, Michael T., Guthikonda, Bharat , Jabbour, Pascal , Salim, Hamza , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Ogilvy, Christopher S , Dmytriw, Adam A , Aslan, Assala , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Abo Kasem, Rahim , Spiotta, Alejandro M , Levitt, Michael R , Altschul, David J , Shakir, Hakeem J , Zaidat, Osama O , Stapleton, Christopher , Koch, Matthew J , Chen, Peng R , Kan, Peter , Choudhri, Omar , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Erginoglu, Ufuk , Li, Yan-Lin , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Kondziolka, Douglas , Dmytriw, Adam A. , Abou‐Al‐Shaar, Hussam , Naamani, Kareem El, Abdelsalam, Ahmed , Kumbhare, Deepak , Mccarthy, Finn, Keleş, Abdullah , Tos, Salem M , Mantziaris, Georgios , Park, Min S, Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Ocampo-Navia, María Isabel , Kasem, Rahim Abo , Kühn, Anna Luisa , Sekhar, Laligam N. , Levitt, Michael R. , Altschul, David , Almajali, Mohammad , See, Alfred P. , Abla, Adib A. , Patel, Aashay , Nguyen, Andrew , Srinivasan, Visish M. , Blackburn, Spiros , Gooch, Michael Reid , Kim, Louis J. , Choudhri, Omar , Simonato, Davide , Savardekar, Amey Rajan , Lawton, Michael T. , Morcos, Jacques J.

Mayo Clinic

Journal of NeuroInterventional Surgery | August 22, 2025 | Volume: 18 | Issue: 8 | Pages: 1765-1772

10.1136/jnis-2025-023873 | PMID 40846482 Get It

Background and objectives Arteriovenous malformations (AVMs) with perinidal aneurysms and single draining vein are associated with an elevated risk of rupture and increased procedural complexity. The role of preoperative embolization in this high-risk anatomical subset remains unclear. This study aimed to evaluate the safety and efficacy of microsurgery with preoperative embolization, compared with microsurgery alone in patients with such AVMs. Methods We conducted a multicenter retrospective analysis of an AVM registry from the MISTA (Multicenter International Study for Treatment of Brain AVMs) consortium and included AVMs with perinidal aneurysms and a single draining vein. Baseline characteristics, angiographic outcomes, functional outcomes, and complication rates were compared. Propensity score weighting (PSW) using the covariate balancing method was applied to adjust for baseline differences. Results Out of a total of 1919 patients, 65 met the inclusion criteria; 45 patients underwent preoperative embolization followed by microsurgery, and 20 underwent microsurgery alone. After adjustment, complete obliteration rates were similar between groups (OR 0.87, 95% CI 0.04 to 16.33, P=0.92), as were rates of functional independence at discharge and follow-up. Overall complication, symptomatic complication, and mortality rates did not differ significantly between groups. However, permanent complications were significantly lower in patients with preoperative embolization (OR 0.06, 95% CI 0.004 to 0.84, P=0.03). Discussion In patients with AVMs featuring perinidal aneurysms and single draining vein, preoperative embolization followed by microsurgery was associated with fewer permanent complications and no increase in adverse outcomes compared with microsurgery alone. However, given the small number of events, this finding should be interpreted cautiously.
Early Thrombolysis and Outcomes in Central Retinal Artery Occlusion: An Individual Participant Data Meta-Analysis
Xie, Jim Shenchu , Chaban, Yuri V. , Lusterio, Adrien , Kaur, Hargun , Motekalem, Yasmin, Zeraatkar, Dena , Althaus, Katharina , Malbin, Brett , Nolte, Christian H. , Pettersen, Jacqueline A. , Woo, Se Joon , Chen, Celia S. , Khrlobyan, Manya, Sangha, Navdeep , Jurado, Elena Ardila, Mattle, Heinrich P. , Nedelmann, Max, Spitzer, Martin S. , Poli, Sven , Hametner, Christian , Baumgartner, Philipp , Kook, Lucas , Dumitrascu, Oana M. , Margolin, Edward , Xie, Jim S , Zaslavsky, Kirill , Chaban, Yuri V , Lusterio, Adrien , Popovic, Marko M , Althaus, Katharina , Malbin, Brett , Nolte, Christian H , Scheitz, Jan F , Pettersen, Jacqueline A , Leker, Ronen R , Kim, Joonhyung , Woo, Se Joon , Chen, Celia , Feltgen, Nicolas , Sangha, Navdeep , Arnold, Marcel , Mattle, Heinrich , Heldner, Mirjam R , Cordonnier, Charlotte , Poli, Sven , Hametner, Christian , Baumgartner, Philipp , Wegener, Susanne , Kook, Lucas , Shahjouei, Shima , Dumitrascu, Oana M , Margolin, Edward M , Heldner, Mirjam R. , Shahjouei, Shima , Michel, Patrik

Mayo Clinic

Stroke | August 20, 2025 | Volume: 56 | Issue: 11 | Pages: 3175-3186

10.1161/strokeaha.124.049955 | PMID 40832714 Get It

BACKGROUND: This individual participant data meta-analysis aimed to determine whether time to treatment influences the effect of intraarterial thrombolysis (IAT), intravenous thrombolysis, and conservative standard therapy on visual outcomes in nonarteritic central retinal artery occlusion. METHODS: We searched MEDLINE, CENTRAL, and Embase up to June 2023 for studies reporting treatment modality and peri-treatment best-corrected visual acuity (BCVA) for ≥5 participants, excluding patients with nonsevere vision loss (BCVA <1.0 logarithm of the minimum angle of resolution [logMAR]) or treated after 24 hours of symptom onset. The primary outcome was recovery from severe vision loss (final BCVA <1.0 logMAR). We used mixed-effect models and local polynomial regression to investigate nonlinear relationships between time to treatment and recovery from severe vision loss. RESULTS: Of 4074 screened studies, individual participant data were sought from 52, with 35 contributing individual participant data for 1038 participants. In total, 783 patients met inclusion criteria (age, 64.8±13.3 years; 35.5% female; baseline BCVA, 2.3±0.5 logMAR). For every hour decrease in time to treatment, thrombolysis was associated with greater improvement in BCVA (intraarterial, 0.02 logMAR [95% CI, 0–0.04]; intravenous, 0.04 logMAR [95% CI, 0.00–0.07]) than conservative standard therapy (0.01 logMAR [95% CI, 0–0.02]). A nonlinear relationship was detected for intraarterial thrombolysis with a changepoint at 8 hours (95% CI, 6.7–9.4). Thrombolysis was associated with increased recovery from severe vision loss compared with conservative standard therapy (intraarterial within 6 hours: odds ratio, 2.72 [95% CI, 1.02–7.28], 27.2% versus 12.0%; intravenous within 4.5 hours: odds ratio, 3.32 [95% CI, 1.24–8.92], 28.8% versus 11.1%). Findings were consistent in subgroup analysis restricted to patients receiving recombinant tissue-type plasminogen activator. Monte-Carlo simulations showed that a randomized controlled trial would require 95 participants per group to achieve 80% power to detect an odds ratio of 3.0 for recovery from severe vision loss. CONCLUSIONS: Early intervention in nonarteritic central retinal artery occlusion is associated with improvement in visual recovery, with intraarterial thrombolysis and intravenous thrombolysis outperforming nonthrombolytic treatments. These findings warrant confirmation in sufficiently powered randomized controlled trials.
Anxiety and Depression in Adults With Vestibular Disorders: A Systematic Review and Meta‐Analysis
Kim, C.H. , McCray, Lauren R. , Nguyen, Shaun A. , Jafri, Shabih , Rizk, Habib G. , Kim, Cory Hyun-Su , Rizk, Habib , Staab, Jeffrey P.

Mayo Clinic

The Laryngoscope | August 15, 2025 | Volume: 136 | Issue: 2 | Pages: 535-546

10.1002/lary.70055 | PMID 40815545 Get It

ABSTRACT Objective To derive precise estimates of anxiety and depressive disorder prevalence in patients with common vestibular disorders. Data Sources CINAHL, Cochrane Library, PubMed, PsycINFO, and SCOPUS. Review Methods This systematic review and meta‐analysis was reported per PRISMA guidelines. Outcomes included continuous measures (mean), proportions (%), and relative risks (RR) with 95% confidence intervals. Results Eighty‐five studies ( n = 764,403) examining anxiety, depression, and vestibular disorders in adults were included. Mean ages were 50.3 (vestibular) and 46.7 (control); females comprised 63.8% and 64.3%, respectively. Patients with vestibular disorders had significantly higher rates and risks of anxiety (31.4% vs. 8.3%, p < 0.0001; RR = 1.50, 95% CI: 1.1–2.0) and depression (28.3% vs. 4.7%, p < 0.0001; RR = 2.9, 95% CI: 1.8–4.4) than controls. Elevated rates were observed in benign paroxysmal positional vertigo (30.6%, 23.6%), Meniere's disease (47.0%, 43.1%), vestibular migraine (46.5%, 35.7%), and vestibular neuritis (19.4%, 20.7%) (all p < 0.0001). Episodic disorders showed higher prevalence than vestibular neuritis. Patients with unspecified peripheral vestibular disorders also had significantly higher anxiety (12.1%) and depression (13.2%) rates than controls. Meta‐regression revealed significant associations between Dizziness Handicap Inventory (DHI) scores and Hospital Anxiety and Depression Scale (HADS) anxiety and depression subscales. Conclusions This meta‐analysis offers the most precise prevalence and relative risk estimates of anxiety and depressive disorders in vestibular illness. The greater risk in episodic versus single‐event vestibular disorders may inform the understanding of vestibular–psychiatric comorbidity mechanisms.
AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome
Nimani, Saranda , Bains, Sahej , Alerni, Nicolò , Ördög, Balázs , Horváth, András , Matas, Lluis , Louradour, Julien , Giammarino, Lucilla , Tester, David J. , Beslac, Olgica, López, Rubén , Meier, Stefan , Christoforou, Nicolas , Barbieri, Miriam , Vashanthakumar, Varjany, Perez‐Feliz, Stefanie , Casalta, L.G. Garcia, Kim, C.S. John, Zhou, Wei , Ye, Dan , Jurgensen, Jacqulyn, Bego, Mariana G. , Keyes, Lisa R., Owens, Jane , Pinkstaff, Jason, Zehender, Manfred, Brunner, Michael, Heijman, Jordi , Casoni, Daniela , Brooks, Gabriel , Odening, Katja E. , Egle, Manuel , Barbieri, Miriam , Christoph, Jan , Brunner, Michael , Heijman, Jordi , Praz, Fabien , Haeberlin, Andreas , Ackerman, Michael J , Odening, Katja E , Bains, Sahej , Vashanthakumar, Varjany, Parodi, Chiara, Barry, Michael A. , Praz, Fabien , Ackerman, Michael

Mayo Clinic

European Heart Journal | August 15, 2025 | Volume: 47 | Issue: 2 | Pages: 199-213

10.1093/eurheartj/ehaf660 | PMID 40884219 Get It

Abstract Background and Aims Type 1 short QT syndrome (SQT1) is a genetic channelopathy caused by gain-of-function variants in KCNH2, resulting in shortened cardiac repolarization and QT intervals, which predispose patients to ventricular arrhythmias and sudden cardiac death. This study aimed to investigate the therapeutic efficacy of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. Methods KCNH2-SupRep was developed by combining a KCNH2-shRNA with its corresponding shRNA-immune KCNH2-cDNA into an AAV9 vector, delivered directly into the aortic root (1 × 1010 vg/kg). Therapeutic efficacy was evaluated in vivo by electrocardiogram, ex vivo by optical mapping, and at cellular levels by patch-clamp, calcium imaging, and qPCR in ventricular cardiomyocytes (VCMs). Results In vivo, KCNH2-SupRep normalized the heart rate-corrected QT interval (QTc) in SQT1 rabbits, without affecting repolarization heterogeneity. Ex vivo, KCNH2-SupRep corrected the action potential duration (APD90) and resolved the increased apicobasal APD90 heterogeneity observed in untreated (UT)-SQT1 hearts, supporting an antiarrhythmic effect, which was further validated by reduced re-entry formation in silico. At cellular levels, KCNH2-SupRep prolonged APD90 in VCMs from SupRep-SQT1 rabbits closer to wildtype levels compared with UT- and sham-SQT1. Additionally, KCNH2-SupRep restored the cellular surrogate of the electro-mechanical window and normalized IKr in nearly 50% of VCMs, in line with a 50%–60% suppression of the mutant KCNH2 transcript. Conclusions This proof-of-concept study is the first to demonstrate the efficacy of gene therapy for SQT1 in a medium-sized animal model. KCNH2-SupRep gene therapy successfully corrected the pathologic phenotype in vivo, ex vivo, and at cellular levels in transgenic SQT1 rabbits.
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma
Greenbaum, Uri , Hashmi, Hamza , Elsawy, Mahmoud , Kim, Soyoung , Moskop, Amy , Oloyede, Temitope, Awan, Farrukh T. , Bachanová, Veronika , Badar, Talha , Bar, Merav , Barba, Pere , Cashen, Amanda F. , Ganguly, Siddhartha , Kittai, Adam S. , Lulla, Premal , Mead, Elena, Geethakumari, Praveen Ramakrishnan , Saber, Wael , Strouse, Christopher , Valluripalli, Anusha, Wudhikarn, Kitsada , Pasquini, Marcelo C. , Dholaria, Bhagirathbhai R , Farooq, Umar , Hematti, Peiman , Hill, LaQuisa C , Jain, Michael D , Jain, Tania , Lulla, Premal D , McGuirk, Joseph , Mussetti, Alberto , Nishihori, Taiga , Olson, Amanda L , Perales, Miguel-Angel , Riedell, Peter A , Shouval, Roni , Magalhaes-Silverman, Margarida , Pasquini, Marcelo , Ahmed, Sairah , Sorror, Mohamed , Bachanova, Veronika , Badar, Talha , Strouse, Christopher S , Awan, Farrukh T , Kim, Soyoung , Moskop, Amy , Beitinjaneh, Amer , Dholaria, Bhagirathbhai , Foglesong, Jessica , Hematti, Peiman , Hill, LaQuisa C. , Jain, Michael D. , Jain, Tania , Kebriaei, Partow , Locke, Frederick L. , McGuirk, Joseph P. , Mussetti, Alberto , Nishihori, Taiga , Pennisi, Martina , Perales, Miguel‐Angel , Riedell, Peter A. , Shpall, Elizabeth J. , Magalhaes‐Silverman, Margarida , Turtle, Cameron J. , Vallurupalli, Anusha , Ahmed, Sairah , Sorror, Mohamed L.

Mayo Clinic

Blood Advances | August 14, 2025 | Volume: 10 | Issue: 1 | Pages: 217-227

10.1182/bloodadvances.2024015599 | PMID 40811818 Get It

Abstract The cumulative impact of baseline comorbidities on outcomes of chimeric antigen receptor T-cell (CAR-T) therapy is not well established. Therefore, we developed and validated a Cellular Therapy Comorbidity Index (CT-CI) to predict outcomes following CD19-directed CAR-T therapy for large B-cell lymphoma (LBCL). Patients aged 18 or older receiving commercial CAR-T therapy for LBCL during 2017 to 2020 were selected from the Center for International Blood and Marrow Transplant Research registry. Patients were randomly assigned to training or validation cohorts. Comorbidities given weighted scores comprised the CT-CI, which was then validated for overall survival (OS) prognostication. A total of 1916 patients from 97 medical centers were included, with a median age of 64 years (19-91 years). About 70% of patients had comorbidities, such as cardiac disease (12%); diabetes (14%); hepatic dysfunction (mild, 8%; moderate to severe, 2%); psychiatric disturbance (18%); and pulmonary dysfunction (moderate, 15%; severe, 12%). The CT-CI was calculated, stratified patients in 3 categories, and was associated with increased mortality. Patients with higher CT-CI scores had worse OS (CT-CI 1: hazard ratio [HR], 1.37 [95% confidence interval [CI], 1.16-1.62; P&lt; .001]; CT-CI 2: HR, 1.49 [95% CI, 1.17-1.89; P = .001]; CT-CI ≥ 3: HR, 2.55 [95% CI, 1.90-3.42; P&lt; .001]). Higher CT-CI scores predicted treatment-related mortality and relapse. There was no correlation between the CT-CI score and CAR-T–related toxicities. The novel CT-CI score stratifies the effect of patient comorbidities on survival after CAR-T therapy and can be used for clinical decision-making and treatment selection in high-risk populations. However, comorbidities and fear of increased toxicity should not preclude patients from this effective therapy.
Redundancy‐weighted FDK reconstruction for dual‐detector combined‐scanning CBCT: Practical implementation for image guided particle therapy
Song, Bongyong , Whitaker, Thomas J. , Gautam, Archana S., Olberg, Sven, Choi, Byongsu , Lee, Sung Uk , Jeong, Jong Hwi , Kim, Jeongheon, Tan, Jun , Lü, Bo , Yaddanapudi, Sridhar , Beltran, Chris , Park, Justin C., Tan, Jun , Furutani, Keith, Beltran, Chris J , Yaddanapudi, Sridhar , Gautam, Archana S., Liang, Xiaoying , Furutani, Keith M. , Tan, Jun

Mayo Clinic

Medical Physics | August 9, 2025 | Volume: 52 | Issue: 8 | Pages: No page available

10.1002/mp.17996 | PMID 40781831 Get It

Abstract Background Cone‐beam computed tomography (CBCT) is essential for image‐guided particle therapy (IGPT), providing daily patient positioning, anatomical monitoring, and treatment verification. However, conventional single‐detector CBCT suffers from poor soft‐tissue contrast, long acquisition times, and motion artifacts, reducing its effectiveness for adaptive radiotherapy workflows. Addressing these challenges requires an advanced CBCT reconstruction approach capable of enhancing image quality while reducing scan time and radiation exposure. Purpose This study introduces a Dual Detector Combined Scanning (DDCS) CBCT reconstruction algorithm to overcome conventional CBCT limitations. By integrating a dual‐source, orthogonal imaging setup, DDCS significantly reduces scanning time and imaging artifacts. A modified Parker‐weighting algorithm further improves image reconstruction accuracy, ensuring high‐fidelity visualization. The goal is to enhance adaptive radiotherapy by improving real‐time patient positioning, dose verification, and motion management. Methods A dual‐detector CBCT system was designed to acquire orthogonal projections simultaneously, reducing scan time and improving data completeness. A modified Parker‐weighting algorithm corrected angular overlap distortions, ensuring better reconstruction accuracy. The system was evaluated using numerical and physical phantom studies to assess spatial resolution, contrast‐to‐noise ratio (CNR), and artifact reduction. Additionally, a dynamic phantom simulated respiratory motion, validating motion robustness for adaptive radiotherapy. Performance was compared against single‐detector CBCT, focusing on image fidelity, noise suppression, and computational efficiency. Results DDCS‐CBCT demonstrated higher CNR, reduced motion artifacts, and improved spatial resolution, leading to more accurate anatomical visualization. The system's efficiency enables faster, more reliable patient setup in IGPT while maintaining a lower imaging dose. Conclusion The proposed DDCS‐CBCT approach significantly improves imaging accuracy, reduces scan time, and enhances real‐time volumetric guidance in IGRT/IGPT. These findings support the clinical feasibility of the DDCS system and its integration into online adaptive radiotherapy workflows.
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives
Carrillo, Marı́a C., Chen, Christopher , Choi, Seong Hye , Fontana, Igor C. , Graff‐Radford, Jonathan, Heidebrink, Judith L. , Hu, Chaur‐Jong , Ihara, Ryoko , Ip, Fanny C.F., Fitri, Fasihah Irfani , Jack, Clifford R. , Yoon, Soo Jin , Jia, Jianping , Kandiah, Nagaendran, Kowa, Hisatomo , Joie, Renaud La , Noritake, Ryoji, Okonkwo, Ozioma C. , Raman, Rema , Shen, Yong , Simuni, Tanya, Snyder, Heather M. , Sriwannopas, Orapitchaya, Wang, Huali , Zhou, Jin , Sexton, Claire E. , Carrillo, María C. , Simuni, Tanya , Chen, Christopher , Mahinrad, Simin , Jack, Clifford R , La Joie, Renaud , Simuni, Tanya , Iwatsubo, Takeshi , Sperling, Reisa Anne , Algeciras‐Schimnich, Alicia , Arai, Hidenori , Barron, Anna M. , Benzinger, Tammie L.S. , Graff‐Radford, Jonathan , Grill, Joshua D. , Ikeuchi, Takeshi , Iwata, Atsushi , Kandiah, Nagaendran , Kim, SangYun , Niimi, Yoshiki , Palmqvist, Sebastian , Rafii, Michael S. , Stoeckel, Luke E. , Flier, Wiesje M. van der , Wilcock, Donna M. , Zetterberg, Henrik , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia | August 5, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70536 | PMID 40760693 Get It

Abstract The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease‐modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment‐induced changes in disease biology. These frameworks enable opportunities for personalized interventions—encompassing pharmacological and non‐pharmacological strategies—and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker‐based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. Highlights Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic‐specific impacts, focusing on Asia.
Developing a novel algorithm to identify incident and prevalent dementia in Medicare claims—the ARIC Study
Wang, Tiansheng , Pate, Virginia , Kim, Dae Hyun , Power, Melinda C. , Garden, Gwenn A. , Palta, Priya, Knopman, David S. , Jonson‐Funk, Michelle , Kucharska‐Newton, Anna , Knopman, David S. , Garden, Gwenn , Palta, Priya , Stürmer, Til , Kucharska-Newton, Anna M , Kim, Dae Hyun

Mayo Clinic

American Journal of Epidemiology | August 1, 2025 | Volume: 194 | Issue: 12 | Pages: 3537-3548

10.1093/aje/kwaf166 | PMID 40754790 Get It

Abstract There is an urgent need to improve dementia ascertainment robustness in real-world studies assessing drug effects on dementia risk. We developed algorithms to dementia identification algorithms using Medicare claims (inpatient/outpatient/prescription) from 3318 Visit 5 (2011-2013) and 1828 Visit 6 (2016-2017) participants of the Atherosclerosis Risk in Communities (ARIC) Study, validated against ARIC's rigorous syndromic dementia classification. Algorithm performance was compared to existing algorithms (Jain, Bynum, Lee). We further evaluated algorithms effectiveness in a 20% random Medicare sample aged ≥70 years who initiating liraglutide or dipeptidyl peptidase 4 inhibitors (DPP4i) to assess 3-year adjusted risk difference (aRD) for dementia. Our incident dementia algorithm required two dementia diagnostic codes within 1-year, or one dementia code plus a new dementia prescription within 90 days. It achieved a positive predictive value (PPV) of 69.2%, specificity of 99.0%, and sensitivity of 34.6% (population prevalence: 8.8%), comparable to extant algorithms (PPV, 58.7–68.6%; sensitivity 25.5–40.4%). Prevalent dementia algorithm (without requiring incident diagnoses/prescriptions) demonstrated similar performance. In the Medicare sample, dementia risk ranged from 3.0% to 12.5%, aRD comparing liraglutide to DPP4i varied −1.2% to −3.6%, with our algorithm closely matching the Bynum algorithm. Algorithm selection significantly impacts treatment effect estimates, highlighting its importance in in pharmacoepidemiologic research.